{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:59:05Z","timestamp":1787828345010,"version":"build-2784847793"},"reference-count":31,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2017.00317","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T04:04:22Z","timestamp":1496117062000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Selective Tissue Distribution Mediates Tissue-Dependent PPAR\u03b3 Activation and Insulin Sensitization by INT131, a Selective PPAR\u03b3 Modulator"],"prefix":"10.3389","volume":"8","author":[{"given":"Xinni","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"Ppargamma signaling and metabolism. The good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/hep.24155","article-title":"Transcription coactivator mediator subunit med1 is required for the development of fatty liver in the mouse","volume":"53","author":"Bai","year":"2011","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.str.2007.07.014","article-title":"Partial agonists activate ppargamma using a helix 12 independent mechanism","volume":"15","author":"Bruning","year":"2007","journal-title":"Structure"},{"key":"B4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1476-5381.2009.00231.x","article-title":"P633h, a novel dual agonist at peroxisome proliferator-activated receptors \u03b1 and \u03b3, with different anti-diabetic effects in db\/db and kk-ay mice","volume":"157","author":"Chen","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of ppargamma by cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1517\/17460441.2015.1100164","article-title":"The tzd insulin sensitizer clue provides a new route into diabetes drug discovery","volume":"10","author":"Colca","year":"2015","journal-title":"Expert Opin. Drug Discov"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.2337\/dc13-2480","article-title":"Can a selective ppargamma modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?","volume":"37","author":"DePaoli","year":"2014","journal-title":"Diabetes Care"},{"key":"B8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jdiacomp.2010.06.006","article-title":"Selective modulation of ppargamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with type 2 diabetes","volume":"25","author":"Dunn","year":"2011","journal-title":"J. Diabetes Complications"},{"key":"B9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1124\/mol.107.041202","article-title":"The differential interactions of peroxisome proliferator-activated receptor gamma ligands with tyr473 is a physical basis for their unique biological activities","volume":"73","author":"Einstein","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"34268","DOI":"10.1074\/jbc.M300043200","article-title":"Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass","volume":"278","author":"Gavrilova","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nm1278","article-title":"Thiazolidinediones expand body fluid volume through ppargamma stimulation of enac-mediated renal salt absorption","volume":"11","author":"Guan","year":"2005","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"15712","DOI":"10.1073\/pnas.2536828100","article-title":"Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle","volume":"100","author":"He","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/nm956","article-title":"Muscle-specific pparg deletion causes insulin resistance","volume":"9","author":"Hevener","year":"2003","journal-title":"Nat. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"267S","DOI":"10.3945\/ajcn.2009.28449E","article-title":"Selective peroxisome proliferator-activated receptor gamma (ppargamma) modulation as a strategy for safer therapeutic ppargamma activation","volume":"91","author":"Higgins","year":"2010","journal-title":"Am. J. Clin. Nutr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1073\/pnas.0306743102","article-title":"Deletion of ppargamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance","volume":"102","author":"Jones","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B16","first-page":"381","article-title":"Int-131, a ppargamma agonist for the treatment of type 2 diabetes","volume":"10","author":"Kintscher","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"E552","DOI":"10.1152\/ajpendo.00569.2011","article-title":"Selective ppargamma modulator int131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice","volume":"302","author":"Lee","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.cell.2005.11.026","article-title":"The many faces of ppargamma","volume":"123","author":"Lehrke","year":"2005","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1074\/jbc.M111.294785","article-title":"Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors","volume":"287","author":"Malapaka","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1210\/endo.141.11.7771","article-title":"Up-regulation of peroxisome proliferator-activated receptors (ppar-\u03b1) and ppar-\u03b3 messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of ppar-\u03b3-responsive adipose tissue-specific genes in the liver of obese diabetic mice","volume":"141","author":"Memon","year":"2000","journal-title":"Endocrinology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jmb.2009.01.025","article-title":"Int131: a selective modulator of ppar gamma","volume":"386","author":"Motani","year":"2009","journal-title":"J. Mol. Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.cmet.2012.01.019","article-title":"Ppargamma agonists induce a white-to-brown fat conversion through stabilization of prdm16 protein","volume":"15","author":"Ohno","year":"2012","journal-title":"Cell Metab."},{"key":"B24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/nature07182","article-title":"Prdm16 controls a brown fat\/skeletal muscle switch","volume":"454","author":"Seale","year":"2008","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1126\/science.1068537","article-title":"Molecular determinants for the tissue specificity of serms","volume":"295","author":"Shang","year":"2002","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","first-page":"22504","DOI":"10.1073\/pnas.0912487106","article-title":"Ppargamma activation in adipocytes is sufficient for systemic insulin sensitization","volume":"106","author":"Sugii","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B27","doi-asserted-by":"publisher","first-page":"18656","DOI":"10.1073\/pnas.1314863110","article-title":"Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of ppargamma","volume":"110","author":"Wang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B28","doi-asserted-by":"publisher","first-page":"867180","DOI":"10.1155\/2011\/867180","article-title":"Thiazolidinediones on ppargamma: the roles in bone remodeling","volume":"2011","author":"Wei","year":"2011","journal-title":"PPAR Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1007\/s00125-013-2920-2","article-title":"Amorfrutin b is an efficient natural peroxisome proliferator-activated receptor gamma (ppargamma) agonist with potent glucose-lowering properties","volume":"56","author":"Weidner","year":"2013","journal-title":"Diabetologia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1248\/bpb.b13-00008","article-title":"C333h ameliorated insulin resistance through selectively modulating peroxisome proliferator-activated receptor gamma in brown adipose tissue of db\/db mice","volume":"36","author":"Zhang","year":"2013","journal-title":"Biol. Pharm. Bull"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00317\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T04:04:25Z","timestamp":1496117065000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fphar.2017.00317\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,30]]},"references-count":31,"alternative-id":["10.3389\/fphar.2017.00317"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2017.00317","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,30]]},"article-number":"317"}}